Advertisement

Tumor Biology

, Volume 33, Issue 5, pp 1719–1725 | Cite as

Expression and association of HER2 with prognosis in early-stage (T1–T2N0M0) non-small cell lung cancer

Research Article

Abstract

The expression of human epidermal growth factor receptor 2 (HER2) is related to tumor progression in many human malignancies. This study evaluated the significance of HER2 in early-stage non-small cell lung cancer (NSCLC). Specimens were obtained from 172 patients with early-stage (T1–T2N0M0) NSCLC, which included T1N0M0 (n = 52) and T2N0M0 (n = 120). The expression of HER2 was determined by immunohistochemistry (IHC). HER2 expression and its relationship with clinicopathological parameters and survival were analyzed. The expression of HER2 was significantly higher in the non-squamous cell carcinoma than in the squamous cell carcinoma (74.3 % vs. 53.7 %, p = 0.008). HER2 expression and tumor size were independent prognostic indicators in the multivariate analysis (p = 0.007 and p = 0.015, respectively). Expression of HER2 indicated a worse 5-year overall survival (65 % vs. 86 %, p = 0.014), especially for stages IB and IIA diseases (p = 0.035 and p = 0.043, respectively) and adenocarcinoma (p = 0.047). Therefore, HER2 may be related with the pathogenesis of NSCLC and act as an unfavorable prognostic factor in T1N0M0 and T2N0M0 NSCLC, especially in stages IB and IIA diseases.

Keywords

Non-small cell lung cancer Prognosis HER2 Immunohistochemistry 

Abbreviations

HER2

Human epidermal growth factor receptor 2

NSCLC

Non-small cell lung cancer

IHC

Immunohistochemistry

ROC

Receiver operating characteristic

OS

Overall survival

AUC

Area under the ROC curve

ORR

Overall response rate

TTP

Time to progression

Notes

Acknowledgments

This study was supported by the Fundamental Research Funds for the Central Universities and the grant from Youth Training Plan of Sun Yat-Sen University (No. 10ykpy38), the Research Award Fund for Outstanding Young Researchers in Sun Yat-Sen Cancer Center (Nos. 303045172006 and 303045172005), the National Natural Science Foundation of China (No. 30901728) and the Science & Technology Pillar Program of Guangdong Province (No. 2011B031800220). The authors declare their independence of sponsors, and the content of this article has not been influenced by the sponsors.

Conflicts of interest

None

References

  1. 1.
    Carney DN. Lung cancer–time to move on from chemotherapy. N Engl J Med. 2002;346:126–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8–29.CrossRefPubMedGoogle Scholar
  3. 3.
    Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European lung cancer working party. J Clin Oncol. 1995;13:1221–30.PubMedGoogle Scholar
  4. 4.
    Metro G, Crinò L. Advances on EGFR mutation for lung cancer. Transl Lung Cancer Res. 2012;1:5–13.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Situ D, Wang J, Shao W, Zhu ZH. Assessment and treatment of cancer pain: from Western to Eastern. Ann Palliat Med. 2012;1:32–44.PubMedGoogle Scholar
  6. 6.
    Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol. 2001;10:139–52.CrossRefPubMedGoogle Scholar
  7. 7.
    Schuell B, Gruenberger T, Scheithauer W, et al. HER 2/neu protein expression in colorectal cancer. BMC Cancer. 2006;6:123.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 2001;7:1850–5.PubMedGoogle Scholar
  9. 9.
    Smith HS. Painful boney metastases. Ann Palliat Med. 2012;1:14–31.PubMedGoogle Scholar
  10. 10.
    Mimura K, Kono K, Hanawa M, et al. Frequencies of HER2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2005;92:1253–60.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Noguchi M, Murakami M, Bennett W, et al. Biological consequences of overexpression of a transfected HER2 gene in immortalized human bronchial epithelial cells. Cancer Res. 1993;53:2035–43.PubMedGoogle Scholar
  12. 12.
    Yu D, Wang SS, Dulski KM, et al. HER2/neu overexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties. Cancer Res. 1994;54:3260–6.PubMedGoogle Scholar
  13. 13.
    Cox G, Jones J, Andi A, et al. A biological staging model for operable non-small cell lung cancer. Thorax. 2001;56:561–6.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Carbognani P, Tincani G, Crafa P, et al. Biological markers in non-small cell lung cancer. Retrospective study of 10-year follow-up after surgery. J Cardiovasc Surg (Torino). 2002;43:545–8.Google Scholar
  15. 15.
    Kuyama S, Hotta K, Tabata M, et al. Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol. 2008;3:477–82.CrossRefPubMedGoogle Scholar
  16. 16.
    Korrapati V, Gaffney M, Larsson LG, et al. Effect of HER2/neu expression on survival in non-small-cell lung cancer. Clin Lung Cancer. 2001;2:216–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Szelachowska J, Jelen M, Kornafel J. Prognostic significance of intracellular laminin and Her2/neu overexpression in non-small cell lung cancer. Anticancer Res. 2006;26:3871–6.PubMedGoogle Scholar
  18. 18.
    Selvaggi G, Scagliotti GV, Torri V, et al. HER2/neu overexpression in patients with radically resected non small cell lung carcinoma. Impact on long-term survival. Cancer. 2002;94:2669–74.CrossRefPubMedGoogle Scholar
  19. 19.
    Tan D, Deeb G, Wang J, et al. HER2/neu protein expression and gene alteration in stage I–IIIA non-small-cell lung cancer: A study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol. 2003;12:201–11.CrossRefPubMedGoogle Scholar
  20. 20.
    Greatens TM, Niehans GA, Rubins JB, et al. Do molecular markers predict survival in non-small-cell lung cancer? Am J Respir Crit Care Med. 1998;157:1093–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Toh CK, Ahmad B, Soong R, et al. Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. J Thorac Oncol. 2010;5:17–22.CrossRefPubMedGoogle Scholar
  22. 22.
    Pelosi G, Del Curto B, Dell’Orto P, et al. Lack of prognostic implications of HER2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I–III neuroendocrine tumours (NET) of the Lung. Int J Cancer. 2005;113:101–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Xu JM, Han Y, Duan HQ, et al. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with Gefitinib. J Cancer Res Clin Oncol. 2009;135:771–82.CrossRefPubMedGoogle Scholar
  24. 24.
    Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92.CrossRefPubMedGoogle Scholar
  25. 25.
    Liu L, Shao X, Gao W, et al. The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: a meta-analysis of published data. J Thorac Oncol. 2010;5:1922–32.CrossRefPubMedGoogle Scholar
  26. 26.
    Takenaka M, Hanagiri T, Shinohara S, et al. The prognostic significance of her2 overexpression in non-small cell lung cancer. Anticancer Res. 2011;31:4631–6.PubMedGoogle Scholar
  27. 27.
    Kern JA, Schwartz DA, Nordberg JE, et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res. 1990;50:5184–7.PubMedGoogle Scholar
  28. 28.
    Weiner DB, Nordberg J, Robinson R, et al. Expression of the neu gene-encoded protein (p185neu) in human non-small cell carcinomas of the lung. Cancer Res. 1990;50:421–5.PubMedGoogle Scholar
  29. 29.
    Awaya H, Takeshima Y, Furonaka O, et al. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol. 2005;58:1076–80.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ochiai A, Akimoto S, Kanai Y, et al. c-erbB-2 gene product associates with catenins in human cancer cells. Biochem Biophys Res Commun. 1994;205:73–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Giatromanolaki A, Koukourakis MI, O’Byrne K, et al. Non-small cell lung cancer: c-erbB-2 overexpression correlates with low angiogenesis and poor prognosis. Anticancer Res. 1999;16:3819–25.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2012

Authors and Affiliations

  1. 1.State Key Laboratory of Oncology in South China, Department of Medical OncologySun Yat-Sen University Cancer CenterGuangzhouChina
  2. 2.State Key Laboratory of Oncology in South China, Department of Thoracic OncologySun Yat-Sen University Cancer CenterGuangzhouChina
  3. 3.State Key Laboratory of Oncology in South China, Department of AnesthesiaSun Yat-Sen University Cancer CenterGuangzhouChina

Personalised recommendations